In 2014, an acute respiratory illness outbreak affected unaccompanied children from Central America entering the United States; 9% of 774 surveyed children were colonized with Streptococcus pneumoniae serotype 5. In our 2015 follow-up survey of 475 children, serotype 5 was not detected, and an interim recommendation to administer 13-valent pneumococcal conjugate vaccine to all unaccompanied children was discontinued.
U naccompanied children are those <18 years of age who entered the United States without legal immigration status and without a Because of the very poor tolerance of previously surgical treatment and high levels of anxiety, the patient and his parents refused destructive therapy. After explaining other therapeutic options, the patient's parents preferred treatment with sinecatechins ointment 10%. The patient's parents were advised that this drug is currently indicated only for treatment of AGWs in adults and (to our knowledge) has never been tested in children and adolescents.
Monotherapy with sinecatechins ointment 10% thrice daily was started; the application was carried out by the patient's mother. At the control visit after only 8 weeks of treatment, almost complete regression of all warts was achieved (Fig. 2) . Parents of the young patient were advised to continue the application for another 2 weeks. Application of sinecatechins ointment 10% was terminated after 10 weeks of treatment. Complete regression without clinical signs of recurrence was seen during the follow-up examinations 4 and 12 weeks after cessation of the treatment. Throughout the treatment period, no adverse events were observed. The patient tolerated the regular application of the ointment without any subjective complaints of pain or pruritus.
DISCUSSION
To our knowledge, this is the first report demonstrating the successful treatment of AGWs with sinecatechins ointment 10% in a pediatric patient. This treatment option was offered to the patient and his parents, even though it is currently indicated only for the treatment of AGWs in adults. This decision was based on our experience with sinecatechins treatment in adults, which has proven to be very well tolerated, and local adverse reactions (e.g., burning or pain) are less common compared with other topical treatments.
Destructive therapeutic methods such as cryotherapy, laser or surgical excision are relatively safe but painful, and in case of recurrent AGWs, repetitive treatment is not well tolerated in children. Surgical excision is therefore often performed under general anesthesia, which may cause several complications. Of the nondestructive methods, few reports have appeared in the literature of successful imiquimod, [5] [6] [7] trichloroacetic acid 8 and podophyllotoxin 6,7 treatment of AGWs in pediatric patients. However, as with sinecatechins, all of these drugs are currently not licensed for the treatment of children.
The efficacy of sinecatechins ointment (both 10% and 15%) has been assessed in 3 randomized studies in an adult immunocompetent population, with complete regression rates ranging from 51% to 61%, and more than 50% regression was observed in over 78% of the patients. The recurrence rates of AGWs observed in these studies 12 weeks after treatment ranged from 4.0% to 11.8%. 4, 9, 10 The complete regression of AGWs seems to be very similar to experience with podophyllotoxin (43%-83%) and imiquimod (55%-81%) though the recurrence rates seem to be lower with sinecatechins ointment than with podophyllotoxin (6%-100%) and imiquimod (6%-26%). parent or legal guardian available to provide care. When unaccompanied children from Central America are apprehended by US Customs and Border Protection, they are referred to the Office of Refugee Resettlement (ORR) for placement in ORR-funded care provider programs. 1 Most children are released to sponsors (ie, qualified parents, guardians, relatives or other adults) in the United States.
During June to July 2014, an outbreak of acute respiratory illness affected unaccompanied children 9-17 years of age in 4 ORRfunded programs and a centralized processing center, preceded by a surge in border crossing that strained the capacity of the US Customs and Border Protection and ORR facilities. The illnesses were caused by multiple pathogens, including Streptococcus pneumoniae (pneumococcus) serotype 5, which was isolated from 6 of 14 hospitalized children with blood cultures. A pneumococcal colonization survey conducted in July 2014 among nonhospitalized children at the 4 affected programs found that serotype 5 was the most frequently isolated serotype [9% (70/774) of surveyed children]. 2 Serotype 5 is rarely isolated in the United States 3 but is included in the 13-valent pneumococcal conjugate vaccine (PCV13). To aid in controlling transmission of pneumococcus, 1 dose of PCV13 was recommended for all unaccompanied children. 4 This recommendation went beyond the routine US recommendation, which targets children <5 years of age 5 and remained in effect after the outbreak had ceased. In 2015, we conducted a follow-up pneumococcal colonization survey to estimate the prevalence of pneumococcal serotype 5 colonization among newly arrived unaccompanied children and to determine whether continued PCV13 vaccination was still warranted for all unaccompanied children.
METHODS
In August 2015, a cross-sectional survey was conducted at 6 ORR-funded programs in Texas. Of the 4 programs surveyed in 2014, only 1 participated in the follow-up survey; the other facilities were no longer operating. Thus, additional programs were selected based on convenience. Children with or without upper respiratory illness who were not known to have active or suspected communicable diseases (eg, varicella, tuberculosis) and had not yet received PCV13 or received PCV13 within 72 hours of the survey were eligible.
The survey included nasopharyngeal specimen collection; brief structured interviews to assess upper respiratory symptoms and antibiotic exposure; and collection of demographics, transit history and PCV13 vaccination history after arrival to the United States from program records. We assessed representativeness of the surveyed population compared with children referred to ORRfunded programs during Fiscal Year (FY) 2015. This was done by using information from a centralized database for unaccompanied children in ORR-funded programs from October 1, 2014 (beginning of fiscal year), to August 27, 2015 (end of survey period). The 2014 survey methods have been described. Briefly, nasopharyngeal swabs and additional data on children's demographics and transit history were collected from assenting nonhospitalized children in the 4 programs.
Laboratory procedures were similar to the 2014 survey. Nasopharyngeal specimens were collected from the child's posterior nasopharynx using flocked swabs, which were immediately placed in 1.0 mL skim milk-tryptone-glucose-glycerol transport medium and placed in a cooler. Within 4-6 hours, specimens were vortexed and kept at −70°C and transported on dry ice to the Streptococcus Laboratory in Atlanta for culture. Supplemented Todd Hewitt broth containing 0.5% yeast extract and 1.0 mL rabbit serum was used for an enrichment step followed by subculture onto blood-agar plates. 6 Optochin susceptibility and bile solubility testing were conducted on any alpha-hemolytic colonies potentially identifiable as pneumococcus. If more than 1 potential pneumococcal colony morphology was identified per plate, representatives of each colony type were tested. Serotypes were obtained by the Quellung reaction. PCV13-serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) were classified as vaccine type; all other serotypes, including nontypeable, were classified as nonvaccine type.
Pneumococcal colonization and serotype distribution were compared with the 2014 results. χ 2 test or Fisher's exact test were used for categorical variables. The Brown-Mood median test was used for continuous variables. Prevalence ratios with 95% confidence intervals were calculated to assess factors associated with vaccine-type colonization.
The survey protocol was reviewed at the Centers for Disease Control and Prevention and determined to be part of public health response; therefore, institutional review board review was not required. Verbal assent in Spanish was obtained from all included Median age of surveyed children was 16 years (range 7-17), similar to the FY 2015 population (range 5-17; P = 0.90). Selfreported fever, cough and sore throat were present in 2%, 14% and 11% of surveyed children, respectively. Antibiotic use within the previous 30 days was reported by 3% of children.
Of None of the factors reviewed (eg, gender, country of origin, duration of travel, presence of upper respiratory symptoms) were associated with prevalence of vaccine-type colonization.
DISCUSSION
The 2015 colonization survey conducted 1 year after an outbreak of acute respiratory illness among unaccompanied children did not detect S. pneumoniae serotype 5, despite serotype 5 being the most frequently isolated serotype during the 2014 outbreak.
We believe that outbreak control interventions in 2014, which included resolution of crowding, 2 may have interrupted transmission of serotype 5 among unaccompanied children. S. pneumoniae serotype 5 is considered to be one of the most outbreak-prone serotypes while being a rare cause of colonization in nonoutbreak settings. 7, 8 The high prevalence of serotype 5 colonization in 2014 was likely because of ongoing transmission during the outbreak, whereas the 2015 results are more reflective of baseline (nonoutbreak) serotype 5 prevalence. Reports from other colonization surveys conducted during and after outbreaks have also shown similar patterns. For example, pneumococcal colonization assessments conducted among healthy contacts during a serotype 5 pneumococcal pneumonia outbreak in a military compound in Israel showed a rapid decrease of serotype 5 colonization from 24% to less than 1% at 24 days after public health interventions (ie, antibiotic prophylaxis and sending the trainees home). 9 Our investigation has some limitations. First, the sampling methods used in the 2014 and 2015 surveys were different: the 2015 survey sampled newly arrived children at ORR-sponsored facilities, and the 2014 survey was conducted in facilities from which hospitalized cases of acute respiratory illness were reported, including 3 temporary facilities that could not be included in the 2015 survey.
Second, the 2015 survey participants may not be representative of the general population of unaccompanied children: compared with children referred during FY 2015, males were overrepresented in the 2015 survey and children from Guatemala were underrepresented, which might have been a result of our not including children entering the United States through Arizona. Historically, Arizona has had the second largest number of border crossings after Texas, 10 and approximately 80% of children apprehended in Arizona and referred to ORR care from October 1, 2014, to August 27, 2015, were from Guatemala (ORR, unpublished data). However, gender and country of origin were not associated with differences in vaccine-type colonization, and serotype 5 was not isolated from these subgroups in the 2015 survey. In addition, country of origin was not associated with serotype 5 colonization in the 2014 survey.
2 Therefore, we believe that our survey results can still be used to guide PCV13 policy for the general population of unaccompanied children.
The 2015 survey results demonstrated significant reduction in serotype 5 colonization prevalence, suggestive of reduced transmission of serotype 5 among newly arrived unaccompanied children. Supported by these findings, Centers for Disease Control and Prevention recommended discontinuation of the interim recommendation to administer PCV13 to all unaccompanied children, with routine PCV13 to continue only for children <5 years of age. This recommendation was implemented on September 17, 2015.
